HC Wainwright Analysts Boost Earnings Estimates for AEON Biopharma, Inc. (NASDAQ:AEON)

AEON Biopharma, Inc. (NASDAQ:AEON) – Stock analysts at HC Wainwright upped their Q1 2024 earnings per share (EPS) estimates for AEON Biopharma in a report issued on Wednesday, April 17th. HC Wainwright analyst D. Tsao now expects that the company will earn ($0.31) per share for the quarter, up from their previous forecast of ($0.39). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for AEON Biopharma’s current full-year earnings is ($1.54) per share. HC Wainwright also issued estimates for AEON Biopharma’s Q2 2024 earnings at ($0.31) EPS, Q3 2024 earnings at ($0.32) EPS, Q4 2024 earnings at ($0.24) EPS, FY2024 earnings at ($1.18) EPS and FY2025 earnings at ($1.16) EPS.

AEON Biopharma Price Performance

Shares of AEON opened at $6.54 on Friday. AEON Biopharma has a one year low of $3.37 and a one year high of $17.17. The stock has a 50-day moving average price of $10.64 and a 200 day moving average price of $7.78.

AEON Biopharma (NASDAQ:AEON) last issued its quarterly earnings results on Friday, March 29th. The company reported ($0.71) EPS for the quarter.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Northern Trust Corp boosted its holdings in AEON Biopharma by 53.4% in the fourth quarter. Northern Trust Corp now owns 49,819 shares of the company’s stock valued at $359,000 after purchasing an additional 17,341 shares during the last quarter. Formidable Asset Management LLC acquired a new stake in AEON Biopharma during the third quarter valued at approximately $360,000. Vanguard Group Inc. acquired a new stake in AEON Biopharma during the third quarter valued at approximately $1,085,000. Finally, Atalaya Capital Management LP acquired a new stake in AEON Biopharma during the third quarter valued at approximately $19,827,000. Hedge funds and other institutional investors own 22.78% of the company’s stock.

About AEON Biopharma

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.